NCT00713323 - A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain. | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

PainPeripheral Neuropathy

Interventions

DRUG

Sativex®

containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

Trial Locations (1)

B91 2JL,

Pain Management Research, Clinical Trials Unit, Netherwood House, Solihull Hospital, Solihull